BMS-986141

DRUG5 trials

Sponsors

Bristol-Myers Squibb

Conditions

Coronary Artery DiseaseHealthy ParticipantsHepatic ImpairmentIschemic StrokeThrombosis

Phase 1

Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS-986141 in Healthy Subjects

CompletedNCT02341638

Bristol-Myers SquibbThrombosis

Start: 2014-09-30End: 2015-09-30Updated: 2017-03-31

A Study to Evaluate the Effect of Diltiazem on the Pharmacokinetics (PK) of BMS-986141 in Healthy Subjects

CompletedNCT02922452

Bristol-Myers SquibbIschemic Stroke

Start: 2016-09-30End: 2016-11-30Updated: 2016-12-20

A Study to Evaluate the Pharmacokinetics of BMS-986141 in Participants With Hepatic Impairment Compared to Healthy Participants

WithdrawnNCT02985632

Bristol-Myers SquibbHepatic Impairment

Start: 2017-01-11End: 2017-07-07Updated: 2017-02-06

Phase 2

Safety and Efficacy Study of a Protease Activated Receptor-4 Antagonist Being Tested to Reduce the Chances of Having Additional Strokes or Mini Strokes

CompletedNCT02671461

Bristol-Myers SquibbThrombosis

Start: 2016-04-25End: 2017-03-31Updated: 2018-12-14

A Study to Evaluate BMS-986141 Added on to Aspirin or Ticagrelor or the Combination, on Thrombus Formation in a Thrombosis Chamber Model in Participants With Stable Coronary Artery Disease and Healthy Participants

CompletedNCT05093790

Bristol-Myers SquibbCoronary Artery Disease, Healthy Participants

Start: 2022-03-25End: 2022-11-14Updated: 2023-12-05

Related Papers

PAR4 Antagonism in Patients With Coronary Artery Disease Receiving Antiplatelet Therapies

Arteriosclerosis Thrombosis and Vascular Biology2024-02-1511 citations

First-in-human study to assess the safety, pharmacokinetics, and pharmacodynamics of BMS-986141, a novel, reversible, small-molecule, PAR4 agonist in non-Japanese and Japanese healthy participants

Platelets2023-07-0217 citations